Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28380647 | 0.73 | SLC18A3 (0.34) | PDE7A | |
| SCHEMBL23714592 | 0.72 | MAPK1 (0.43) | PDE7AMAPK1 | |
| SCHEMBL10801442 | 0.72 | MAPK1 (0.39) | PDE7AMAPK1 | |
| SCHEMBL21222493 | 0.72 | MAPK1 (0.39) | PDE7AMAPK1 | |
| SCHEMBL10801437 | 0.72 | MAPK1 (0.39) | PDE7AMAPK1 | |
| SCHEMBL13455119 | 0.71 | NPY5R (0.41) | PDE7AKMT2AMAPK1 | |
| Hydrochloric Acid SCHEMBL10811192 | 0.70 | MAPK1 (0.38) | PDE7AMAPK1 | |
| Hydrochloric Acid SCHEMBL11148872 | 0.70 | MAPK1 (0.38) | PDE7AMAPK1 | |
| SCHEMBL20959484 | 0.70 | PDE7A (0.38) | PDE7AALDH1A1 | |
| SCHEMBL16764537 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032651-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-04-17 | — | — | CN | disclosed |
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | HDAC6, HDAC1, HDAC5 | PDE7A 3038/4885THRB 3219/4885MEN1 4110/4885 |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | HDAC1, HDAC5, HDAC6 | PDE7A 2936/4885THRB 3549/4885MEN1 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.